Tyler Jacks

Tyler Jacks, PhD, is the Director of the Koch Institute for Integrative Cancer Research at MIT, an Investigator of the Howard Hughes Medical Institute, and a Daniel K. Ludwig Scholar. Over the course of his career, Tyler has pioneered the use of gene targeting technology to study cancer-associated genes and to construct models of many human cancer types, including cancers of the lung, pancreas, brain and ovary.

Tyler has served on the Board of Scientific Advisors of the National Cancer Institute and is a former president of the American Association of Cancer Research. He has served as an advisor to several biotechnology and pharmaceutical companies and is a founder of T2 Biosystems, a publicly-traded molecular diagnostics company, and Dragonfly Therapeutics. He is currently a member of the Board of Directors of Amgen and Thermo Fisher Scientific. He was elected to the National Academy of Sciences and the National Academy of Medicine in 2009 as well as the American Academy of Arts and Sciences in 2012.  He is a former winner of the Paul Marks Prize for Cancer Research from the Memorial Sloan Kettering Cancer Center (2005), UCSF Alumni of the Year Award (2014) as well as the 2015 MIT Killian Faculty Achievement Award.